CAS: 779353-01-4; (S)-3-(((3-Ethyl-5-(2-(2-Hydroxyethyl)Piperidin-1-yl)Pyrazolo[1,5-A]Pyrimidin-7-yl)Amino)Methyl)Pyridine 1-Oxide

该化合物是环状腺依赖性动脉(CDKs)的一种有作用和选择性的小分子抑制器,主要针对CDK2,CDK5,CDK1和CDK9. 它显示出高抑制性活动,干扰细胞循环的进化和转录调节,使其成为肿瘤研究的宝贵工具. 氨基丙基苯甲丙胺的动作机制包括诱发人口拥挤和抑制恶性细胞,特别是血解和固体肿瘤中的扩散. 它独特的选择性特征使其有别于泛CDK抑制剂,减少了离目标效果. 化合物在临床试验中受到调查,以了解其在慢性淋巴白血病(CLL)和乳腺癌等癌症中的潜在治疗效果. 它的强健的药性皮肤学特性进一步支持其在临床前和临床研究中的效用.

结构式图片

欧盟法规

C&L通报

上下游产品

5-chloro-3-ethyl-N-[(1-oxido-pyridinyl)methyl]pyrazolo-[1,5-a]pyrimidine-5.7(4H,6H)-dion-7-amine (2S)-2-(2-methoxyethyl)piperidine

合成工艺路线路线简述

    (S)-(-)-2-哌啶乙醇,3-(((5-氯-3-乙基吡唑并[1,5-A]嘧啶-7-基)氨基)甲基)吡啶1-氧化物置于sodium Carbonate体系中,用 N-甲基吡咯烷酮,水 作为反应溶剂,化学反应 12.0H,反应生成 (2S)-1-[3-乙基-7-[[(1-氧代-3-吡啶基)甲基]氨基]吡唑并[1,5-A]嘧啶-5-基]-2-哌啶乙醇
    参考文献:Process And Intermediates For The Synthesis Of (3-Alkyl-5-Piperidin-1-Yl-3,3A-Dihydro-Pyrazolo[1,5-A]Pyrimidin-7-yl)-Amino Derivatives And Intermediates
    标题:Process And Intermediates For The Synthesis Of (3-Alkyl-5-Piperidin-1-Yl-3,3A-Dihydro-Pyrazolo[1,5-A]Pyrimidin-7-yl)-Amino Derivatives And Intermediates
    摘要:该申请公开了一种合成(3-烷基-5-哌啶-1-基-3,3A-二氢-吡唑啉[1,5-A]嘧啶-7-基)-氨基衍生物的新工艺,以及在合成过程中有用的中间体.所述(3-烷基-5-哌啶-1-基-3,3A-二氢-吡唑啉[1,5-A]嘧啶-7-基)-氨基衍生物在制药制剂中作为细胞周期蛋白依赖激酶抑制剂化合物(cdk抑制剂)具有用途.

    海关参考信息

    专利信息


    专利号:US-8076479-B2
    优先权日:2006-08-28
    标题 :Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates
    发明人:CHEN FRANK XING; KEERTIKAR KARTIK M; KUO SHEN-CHUN; LEE HONG-CHANG; RAGHAVAN RAMANI R; WU GEORGE G; XIE JI
    权利人:CHEN FRANK XING; KEERTIKAR KARTIK M; KUO SHEN-CHUN; LEE HONG-CHANG; RAGHAVAN RAMANI R; WU GEORGE G; XIE JI; SCHERING CORP
    摘要:Disclosed is a process for the synthesis of compounds of Formula I n nby sequentially aminating, first with a primary amine and then with a secondary amine, an intermediate compound of the structure of Formula E1,n n nwherein R 1 is a linear, branched, or cyclic alkyloxy functional group of the structure (—R 2a —OH), R 2a is a linear, branched or cyclic alkyl group, R 2 is a linear, branched or cyclic alkyl group, and R 3 is an alkylene-heterocycle, said process comprising forming intermediate compound of Formula E1 by reacting, in a refluxing reaction solvent selected from alcohols having 5 or less carbon atoms and mixtures of two or more thereof, a methanol solution of a salt of a 4-alkyl-3-amino-pyrazole compound of Formula C1,n n nwith a diamidization reagent selected from dimethylmalonate, monomethylmalonyl-chloride, and malonyl dichloride in the presence of a Lewis base having sufficient proton affinity to abstract a proton from the 1-position nitrogen on the pyrazole ring.

    专利号:US-12391691-B2
    优先权日:2018-11-16
    标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
    发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
    权利人:AMGEN INC
    摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

    专利号:US-2025206736-A1
    优先权日:2019-11-14
    标题 :Synthesis of kras g12c inhibitor compound
    发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
    权利人:AMGEN INC
    摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

    专利号:US-12043612-B2
    优先权日:2020-05-09
    标 题 :Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
    发明人:ALLAN LAURA E N; CHEN CHUNGPIN HERMAN; DONG HANQING; GROSSO JOHN A; HASKELL III ROYAL J; LLOYD RHYS; REECE HAYLEY
    权利人:ARVINAS OPERATIONS INC
    摘要:The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A:The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

    专利号:US-7786306-B2
    优先权日:2006-08-18
    标 题 :Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same
    发明人:CHEN FRANK XING; TAMAREZ MARIA M; XIE JI
    权利人:SCHERING CORP
    摘要:The present invention provides a method of resolving piperdin-yl-alkylene-alcohols, in high yield at high enantiomeric purity, for example 2-piperidin-2-yl-ethanol.

    专利号:US-2018371021-A1
    优先权日:2017-05-11
    标 题 :Peptidomimetic macrocycles and uses thereof
    发明人:AIVADO MANUEL; GUERLAVAIS VINCENT; OLSON KAREN
    权利人:AILERON THERAPEUTICS INC
    摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.
    常州安奈凯医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.anikare.com
    企业联系电话:0519-83598696;18018249389👤
    📞常州安奈凯医药科技有限公司 ⚠️参考联系方式
    联系人:蒋经理
    电话:0519-83598696;18018249389
    手机:18018249389
    传真:0519-83598696
    邮箱:info@anikare.com,sales@anikare.com
    通信地址: 江苏省常州市钟楼区龙城大道2239号 智谷工场
    邮编: 213018
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省常州市钟楼区龙城大道2239号 智谷工场
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Nemunaitis JJ, Small KA, Kirschmeier P, Zhang D, Zhu Y, Jou YM, Statkevich P, Yao SL, Bannerji R. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med. 2013 Oct 16;11(1):259. [Epub ahead of print]
    2: Martin MP, Olesen SH, Georg GI, Schönbrunn E. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol. 2013 Nov 15;8(11):2360-5. doi: 10.1021/cb4003283. Epub 2013 Sep 10.
    3: Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. doi: 10.1007/s00280-013-2249-z. Epub 2013 Aug 15.

    合成参考文献


    参考文献:10.1007/s00726-015-2114-y
    摘要:Ianes C, Xu P, Werz N, Meng Z, Henne-Bruns D, Bischof J, Knippschild U. CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation. Amino Acids. 2016 Feb;48(2):579–92. doi: 10.1007/s00726-015-2114-y.
    参考文献:10.1186/s12864-017-3519-7
    摘要:Way GP, Allaway RJ, Bouley SJ, Fadul CE, Sanchez Y, Greene CS. A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. BMC Genomics. 2017 Feb 06;18(1):127.
    参考文献:10.1186/s13058-019-1161-9
    摘要:McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, Smid M, Zhang Y, van de Water B. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. Breast Cancer Research. 2019 Jul 01;21(1):77. doi: 10.1186/s13058-019-1161-9.
    参考文献:10.1038/s41388-020-01412-x
    摘要:Lin B, Li Y, Wang T, Qiu Y, Chen Z, Zhao K, Lu N. CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK. Oncogene. 2020 Sep;39(37):6024–40. doi: 10.1038/s41388-020-01412-x.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知